What happens when a biopharma company responds to a pandemic with a well thought out, scientifically sound plan to address it immediately?
That company’s stock soars while the rest of the top players in biopharma are losing a whopping 7.9% in combined market value due to COVID-19.
At least, that’s what happened in the first quarter for Gilead Sciences and Regeneron, which saw their market caps grow 14.5% and 32.5%, respectively. In fact, they were two of just seven companies among the top 20 pharma players by market cap that charted gains as the COVID-19 pandemic swept across the globe. The aggregate market cap of the top 20 players dropped to $2.6 trillion, according to a new report from GlobalData.
Regeneron’s gain isn’t entirely surprising, given how early it jumped in with an ambitious plan to tackle COVID-19. In mid-March, Regeneron announced it had isolated antibodies from mouse models and human survivors of COVID-19 that could neutralize the virus. Now, it’s preparing an antibody cocktail for a summer clinical trial.
But that wasn’t Regeneron’s only strategy for combating the pandemic. It was simultaneously working with longtime partner Sanofi to repurpose their shared IL-6 inhibitor Kevzara as a COVID-19 treatment. By the end of March, Kevzara was being tested in two pivotal coronavirus clinical trials.
Gilead has also garnered kudos for hustling its experimental treatment remdesivir into clinical trials—and into hospitals for use on a compassionate basis in patients fighting COVID-19. Earlier this month, Gilead CEO Daniel O’Day said the company had slashed the manufacturing timeline for the drug and ramped up production so it could churn out 1 million remdesivir treatment courses by the end of the year.
Roche, which is testing its rheumatoid arthritis drug Actemra in COVID-19, had a 3.6% gain in market value in the first quarter. The drug was already performing well: Actemra sales jumped 30% to CHF 666 million ($687 million) in the first quarter, Roche said yesterday.
But not all of the COVID-19 hopefuls were rewarded by investors in the first quarter. Interestingly, longtime Regeneron partner Sanofi saw its market cap drop nearly 12% despite the fact that it stands to gain if Kevzara succeeds in COVID-19. What’s more, the company recently teamed with GlaxoSmithKline to develop a vaccine against the disease. Still, Sanofi is grappling with other challenges, not the least of which is pressure from Wall Street to freshen up its pipeline even more.
A few other prominent COVID-19 players suffered market-cap losses in the first quarter. They included Pfizer (down 16.5%) and Johnson & Johnson (down 10%). Pfizer is about to launch a COVID-19 vaccine trial with BioNTech, but threats to its core business—like the patent expiration on pain drug Lyrica—caused its revenues to fall 4% last year.
As for J&J, which is also racing to develop a COVID-19 vaccine, it’s the biggest pharma company by revenue and market cap, but it’s also facing its share of challenges. One of its top sellers, Remicade, has been trounced by generic competition, as has its prostate cancer drug Zytiga. J&J’s nagging legal issues—which include opioid trial losses and the ongoing talc lawsuits—haven’t helped soothe investors.
The good news for Big Pharma in the first quarter is that the cumulative 7.9% drop in market cap actually wasn’t as bad as it might seem, GlobalData said. The Dow Jones industrial average, after all, had its worst first-quarter performance ever, losing 23%.
“The reversal of fortune, due to COVID-19, may seem dramatic due to these companies’ long-term growth, however, the effect on the pharmaceutical industry has been mild compared to other industries,” Peter Shapiro, senior director of drugs and business fundamentals for GlobalData, said in the report.
By: Arlene Weintraub
Source: Fierce Pharma
The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.